Akron Children's Hospital > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Privigen Randomized Study for Pediatric CIDP

Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP

Description:

See complete study information on clinicaltrials.gov.

Who May Qualify?:

Male or female patients 2 to <17 years of age with confirmed or possible chronic inflammatory demyelinating polyneuropathy (CIDP)

Who Does Not Qualify:

Patients with:

History or family history of inherited neuropathy
Diagnosed developmental delay or regression
History of thrombotic episode
Known or suspected hypersensitivity to Privigen
Known allergic or other severe reactions to blood products
Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study
Pregnant or breastfeeding mother

Interested in participating?

We are currently recruiting

Study Sponsor:

CSL Behring

Full IRB Study Title:

Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP

IRB Study ID:

23875646

If you are interested in this study or have questions about your child's eligibility, please contact:

Hilary Tonni, Rebecca D. Considine Research Institute: 330-543-4734

Lead Investigator

Ian Rossman, MD, PhD

Pediatric Neurologist
NeuroDevelopmental Science CenterPediatric Neuromuscular ClinicPediatric NeurologyMitochondrial Center

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...